Hospital de Clinicas de Niteroi to acquire Samaritano

Amilpar (BM&FBovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3 SA), the largest healthcare company in Brazil, in accordance with CVM Instruction 358, of January 3, 2002, informs that the Hospital de Clinicas de Niteroi Ltda. ("HCN"), a company owned by our indirect controlling shareholder, has signed an Agreement to acquire up to 100% of the shares representatives of the capital stock of Hospital Samaritano ("Samaritano") for the total amount of R$ 180 million, to be paid as follows: R$ 47 million at the signing of the final Agreement (after an auditing process), R$ 43 million on July 10, 2011 and the balance in 4 equal, biannual and successive installments, the first being on January 10, 2012. HCN will take over Samaritano's liabilities and contingencies up to the limit of R$ 5 million. This deal has as suspensive factor the auditing process, to be concluded up to 90 days.

After the aforementioned auditing process and the accomplishment of the suspensive conditions, this acquisition, as well as all the other involved related parties, will be subject to Amilpar's Board of Directors approval (Due to the Price-Arrangement and Right of First Refusal Agreement - Contrato de Assuncao de Obrigacoes e Outras Avencas - signed between Amilpar and its controlling shareholders), in which Amilpar has the option, through its Board of Directors, to decide over the convenience of the exercise of the right of first refusal on the purchase of Samaritano by Amilpar or its subsidiaries.

Samaritano is located in the south region of the city of Rio de Janeiro, has 93 beds and is renowned as the best hospital in this town and one of the best in Brazil. The annual revenue of the hospital is approximately R$ 210 million.